How to appeal a Cigna prostate cancer denial
ACA §2719 + ERISA §503 · 180-day window · 30-day decision
To appeal a Cigna prostate cancer denial, file an internal appeal within 180 days of the date on the denial letter through Cigna's member or provider portal, under ACA §2719 + ERISA §503. Cigna returns standard decisions in 30 days; if it upholds the denial you can request an independent external review within 4 months.
The framework that applies to your appeal
Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.
Cigna-specific note: Sold its Medicaid Advantage book to HCSC in 2023. Express Scripts (PBM) is Cigna-owned. Frequent class-action litigation around mental health parity.
What Cigna's policy requires for prostate cancer
Cited policy: Cigna Nubeqa (Darolutamide) Coverage Policy
(a) nmCRPC with PSA-doubling-time ≤10 mo on continuous ADT (ARAMIS); OR (b) mHSPC in combination with docetaxel + ADT (ARASENS); OR (c) mHSPC monotherapy + ADT (ARANOTE per Nov 2024 label). Castrate testosterone <50 ng/dL. Darolutamide 600 mg PO BID with food. ECOG 0-2.
How Cigna denies prostate cancer — and how to counter it
Where Cigna pushes back: 1) Try generic abiraterone first (cheaper); 2) Triplet ARASENS 'too toxic'; 3) nmCRPC PSADT documentation insufficient.
Counter-arguments that hold up: ARAMIS NEJM 2019 Fizazi — darolutamide nmCRPC MFS HR 0.41 + final OS HR 0.69. ARASENS NEJM 2022 Smith — triplet darolutamide+docetaxel+ADT OS HR 0.68 (32.5% reduction); AE frequency similar to placebo arm — most AEs were docetaxel-related, NOT darolutamide. Darolutamide has favorable BBB penetration profile (lowest CNS AE rate of all ARSIs — minimal seizure / fatigue / falls vs enzalutamide / apalutamide). NCCN v1.2025 Preferred. Abiraterone requires concomitant prednisone (steroid burden); darolutamide does not. EAU 2024 + ESMO 2024 endorse triplet for de-novo high-volume mHSPC.
What Cigna typically denies for prostate cancer
Across Cigna's commercial and Medicare books, denials cluster around a small number of patterns. For prostate cancer, expect:
- Mental health parity violations
- Step therapy
- Specialty drug prior auth
- OON balance billing disputes
Treatments most often denied in this category
These are the prostate cancer treatments most often flagged for prior auth, step therapy, or medical necessity review:
- Pluvicto (177Lu-PSMA-617)
- Xofigo (radium-223)
- Xtandi (enzalutamide)
- Erleada (apalutamide)
- Nubeqa (darolutamide)
- Zytiga (abiraterone)
How to submit the appeal to Cigna
- Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
- Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Cigna cited in the denial.
- File the appeal through Cigna's portal (members: https://my.cigna.com ; providers: https://cignaforhcp.cigna.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
- If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In CT, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.
Clinician or prior-auth team handling this on the practice side? See Cigna's prior-authorization criteria by drug: Cigna PA criteria on ApprovalHelp.
Frequently asked questions
How long do I have to appeal a Cigna prostate cancer denial?
Cigna allows 180 days from the date on the denial letter to file an internal appeal. Standard decisions come back within 30 days; expedited decisions for urgent care typically within 72 hours.
What's the fastest way to submit a Cigna appeal?
Members can submit through the Cigna member portal at https://my.cigna.com. Providers should use the provider portal at https://cignaforhcp.cigna.com. Faxed and mailed appeals are accepted but take longer.
What denials does Cigna most often issue for prostate cancer?
For prostate cancer, Cigna most often denies on: 1) Try generic abiraterone first (cheaper); 2) Triplet ARASENS 'too toxic'; 3) nmCRPC PSADT documentation insufficient. The strongest counters: ARAMIS NEJM 2019 Fizazi — darolutamide nmCRPC MFS HR 0.41 + final OS HR 0.69. ARASENS NEJM 2022 Smith — triplet darolutamide+docetaxel+ADT OS HR 0.68 (32.5% reduction); AE frequency similar to placebo arm — most AEs were docetaxel-related, NOT darolutamide. Darolutamide has favorable BBB penetration profile (lowest CNS AE rate of all ARSIs — minimal seizure / fatigue / falls vs enzalutamide / apalutamide). NCCN v1.2025 Preferred. Abiraterone requires concomitant prednisone (steroid burden); darolutamide does not. EAU 2024 + ESMO 2024 endorse triplet for de-novo high-volume mHSPC.
What if Cigna denies the appeal too?
After an internal appeal denial you have the right to an external review by an independent reviewer (IRO) — request it within 4 months of the final internal denial.
Related appeal guides
Start your Prostate cancer appeal
Upload your Cigna denial letter — DenialHelp drafts a physician-ready appeal in five minutes, aligned to ACA §2719 + ERISA §503.
Get started →Contact: hello@denialhelp.com